Drug intelligence / Profile preview

JSI-401

Development stage: Phase 1
Lead developer: Junshi Biosciences
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

JSI-401 is a small interfering RNA (siRNA) drug developed by Shanghai Junshi Biosciences. It targets angiopoietin-like protein 3 (ANGPTL3) messenger RNA (mRNA), inhibiting the expression of ANGPTL3 protein through RNA interference. The primary indication under investigation is hyperlipidaemia, with the drug currently in Phase I clinical trials in adults in China. JSI-401 represents a new molecular entity and is classified as an antihyperlipidaemic agent[1].

Other names: JS 401JS401JS-401

Targets

ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on JSI-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JSI-401.

Explore the full profile